Special Situation Investments Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Special Situation Investments

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Paul H. Christiansen	10/13/2021 12:31:25 PM
	of 9

Here's the answer . . . Shares of Jasper Therapeutics Inc. JSPR, +120.80% soared 106.2% in volatile morning trading, enough to pace the Nasdaq's gainers, after Oppenheimer analyst Jay Olson's bullish endorsement the day after the stock closed at a record low. The stock had been halted for volatility twice in the first half hour after the open, as trading volume swelled to 20.7 million shares. The company started trading as a biotechnology company with its "JSPR" ticker after the closing of the acquisition by special purpose acquisition company (SPAC) Amplitude Healthcare Acquisition Corp. was announced after the Sept. 24 close. From that day through Tuesday, the stock had plunged 52.3%, while the S&P 500 SPX, +0.02% slipped 2.4% over the same time. Oppenheimer's Olson initiated Jasper with an outperform rating and stock price target of $21, implying a further 41% gain from current levels. "We view [Jasper] as an emerging leader in the development of novel targeted conditioning agents for hematopoietic stem cell transplantation (HSCT) with lead candidate JSP191 and proprietary engineered hematopoietic stem cell (eHSC) platform," Olson wrote in a note to clients.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next